Tubulysin H is primarily investigated for its potent anticancer properties. It functions by disrupting microtubule dynamics, which are essential for cell division, making it highly effective in targeting rapidly dividing cancer cells. Researchers are exploring its potential in developing targeted cancer therapies, particularly for tumors that are resistant to conventional treatments. Its high cytotoxicity is leveraged in antibody-drug conjugates (ADCs), where it is linked to antibodies that specifically bind to cancer cells, minimizing damage to healthy tissues. Tubulysin H is also studied in preclinical models to understand its mechanisms and optimize its therapeutic applications.